Clinical Trial Update: Systolic Hypertension in the Elderly Program (SHEP) [Phase 3]

View source ↗

Summary

Phase 3 SHEP trial on treating systolic hypertension in elderly adults has completed, evaluating impact on cardiovascular and cerebrovascular outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Cerebrovascular Disease
• Heart Disease
• Hypertension

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Cardiovascular Diseases, Cerebrovascular Disorders | Phase 3 | Status: COMPLETED